Slide 1: Interim Report January – June 2024
Interim Report January – June 2024 August 13th, 2024
Slide 2: Disclaimer
Disclaimer The purpose of this presentation (the "Presentation") is to provide an overview of Moberg Pharma AB (publ) (the "Company"). For the purposes of this notice, "Presentation" means this document, its contents or any part of it, any oral presentation, any question or answer session and any wr
Slide 3: Potential new global market leader in Onychomycosis
Potential new global market leader in Onychomycosis MOB-015 has demonstrated Partnerships in place – potential Launch ongoing under brand name world-leading ability to milestones of USD 70m Terclara® kill nail fungus • 76%1 of patients became fungus • Terclara® became the market free, in two phase 3
Slide 4: Significant events during Q2 2024
Significant events during Q2 2024 • Terclara® is the market leader in Sweden – the aim for the Swedish launch has thus already been accomplished. This success reaffirms our strategy and gives us a solid foundation to build on as we prepare to expand into new markets. • National approvals received fo
Slide 5: Terclara is no 1 in Sweden already from launch
Terclara® is no 1 in Sweden already from launch • We can look back at a successful launch in Sweden, where MOB-015 under the brand name Terclara® quickly became established as the market leader. Terclara® became the market leader already in April, the first month with consumer marketing, and has sin
Slide 6: Commercialization rollout of MOB-015
Commercialization rollout of MOB-015 Two-step process, driven by: 1. Need to secure sufficient terbinafine for a pan-European launch* 2. Moberg Pharma believe the results in the ongoing North American study is likely to strengthen the product claims further, including a shorter dosing regimen with t
Slide 7: MOB-015 approval in EU
MOB-015 approval in EU >50% of countries approved as OTC already from start National approval in 13 European countries • The approval in the European Union represents the first marketing authorization for Moberg Pharma´s new onychomycosis treatment worldwide. • Approval supported by two Phase 3 tria
Slide 8: Additional phase 3 study in North America ongoing
Additional phase 3 study in North America ongoing The North American Phase 3 study is progressing according to plan • Similar design as the already completed North American study – Multi-center, double-blind, randomized, vehicle-controlled study – Includes 384 patients in North America, 50% complete
Slide 9: US commercialization ongoing
US commercialization ongoing • US Strategy - utilize the full potential and the knowledge from our first-generation product Kerasal Nail® – Build our own presence in the US market for podiatrists – Collaborate with a company with an established sales force for dermatologists • Collaboration with Bac
Slide 10: Strengthened Cash Position and Shareholder Base
Strengthened Cash Position and Shareholder Base • When we designed the oversubscribed units issuance (consisting of shares and warrants TO 2) last summer, the intention was to raise approximately SEK 200 million, with half to be realized through the TO 2 warrants. • The outcome of TO 2, with a subsc
Slide 11: Key Financials
Key Financials Last five quarters (SEK thousand) Apr-Jun Jan-Mar Oct-Dec Jul-sep Apr-Jun 2024 2024 2023 2023 2023 Net revenue 4,109 820 - - - Launch of Terclara in Sweden Cost of goods sold -1,388 -328 - - - initiated in February. Q2 Gross profit 2,721 492 - - - represents first full quarter of sale
Slide 12: Potential new global market leader in Onychomycosis
Potential new global market leader in Onychomycosis MOB-015 has demonstrated Partnerships in place – potential Launch ongoing under brand name world-leading ability to milestones of USD 70m Terclara® kill nail fungus • 76%1 of patients became fungus • Terclara® became the market free, in two phase 3
Slide 13: Moberg Pharma AB (Publ)
Moberg Pharma AB (Publ) Gustavslundsvägen 42, 5 tr. 167 51 Bromma mobergpharma.se